Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NCSTN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NCSTN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NCSTN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NCSTN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NCSTN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NCSTN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NCSTN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048872210 | Thyroid | ATC | homeostasis of number of cells | 135/6293 | 272/18723 | 2.92e-08 | 5.50e-07 | 135 |
GO:000226234 | Thyroid | ATC | myeloid cell homeostasis | 84/6293 | 157/18723 | 2.12e-07 | 3.33e-06 | 84 |
GO:005140227 | Thyroid | ATC | neuron apoptotic process | 120/6293 | 246/18723 | 5.41e-07 | 7.75e-06 | 120 |
GO:0051604110 | Thyroid | ATC | protein maturation | 136/6293 | 294/18723 | 4.00e-06 | 4.42e-05 | 136 |
GO:005254734 | Thyroid | ATC | regulation of peptidase activity | 200/6293 | 461/18723 | 6.25e-06 | 6.52e-05 | 200 |
GO:0010038210 | Thyroid | ATC | response to metal ion | 165/6293 | 373/18723 | 1.07e-05 | 1.05e-04 | 165 |
GO:003361914 | Thyroid | ATC | membrane protein proteolysis | 35/6293 | 57/18723 | 1.58e-05 | 1.46e-04 | 35 |
GO:001095233 | Thyroid | ATC | positive regulation of peptidase activity | 94/6293 | 197/18723 | 2.67e-05 | 2.28e-04 | 94 |
GO:000650922 | Thyroid | ATC | membrane protein ectodomain proteolysis | 27/6293 | 43/18723 | 8.44e-05 | 6.30e-04 | 27 |
GO:005254834 | Thyroid | ATC | regulation of endopeptidase activity | 181/6293 | 432/18723 | 1.70e-04 | 1.16e-03 | 181 |
GO:001648515 | Thyroid | ATC | protein processing | 100/6293 | 225/18723 | 4.39e-04 | 2.62e-03 | 100 |
GO:000721915 | Thyroid | ATC | Notch signaling pathway | 79/6293 | 172/18723 | 5.08e-04 | 2.96e-03 | 79 |
GO:005159225 | Thyroid | ATC | response to calcium ion | 69/6293 | 149/18723 | 8.43e-04 | 4.62e-03 | 69 |
GO:004206323 | Thyroid | ATC | gliogenesis | 127/6293 | 301/18723 | 1.07e-03 | 5.66e-03 | 127 |
GO:007124124 | Thyroid | ATC | cellular response to inorganic substance | 98/6293 | 226/18723 | 1.35e-03 | 7.02e-03 | 98 |
GO:00425526 | Thyroid | ATC | myelination | 62/6293 | 134/18723 | 1.54e-03 | 7.84e-03 | 62 |
GO:001095033 | Thyroid | ATC | positive regulation of endopeptidase activity | 79/6293 | 179/18723 | 2.09e-03 | 9.86e-03 | 79 |
GO:00072726 | Thyroid | ATC | ensheathment of neurons | 62/6293 | 136/18723 | 2.39e-03 | 1.11e-02 | 62 |
GO:00083666 | Thyroid | ATC | axon ensheathment | 62/6293 | 136/18723 | 2.39e-03 | 1.11e-02 | 62 |
GO:0050673111 | Thyroid | ATC | epithelial cell proliferation | 174/6293 | 437/18723 | 3.49e-03 | 1.55e-02 | 174 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NCSTN | SNV | Missense_Mutation | | c.170N>G | p.Thr57Ser | p.T57S | Q92542 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
NCSTN | SNV | Missense_Mutation | | c.1420G>C | p.Glu474Gln | p.E474Q | Q92542 | protein_coding | deleterious(0.03) | benign(0.238) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NCSTN | SNV | Missense_Mutation | | c.2070C>G | p.Ile690Met | p.I690M | Q92542 | protein_coding | tolerated(0.06) | benign(0.067) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NCSTN | SNV | Missense_Mutation | novel | c.1715C>T | p.Ala572Val | p.A572V | Q92542 | protein_coding | deleterious(0.02) | possibly_damaging(0.787) | TCGA-E9-A3Q9-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphane | CR |
NCSTN | SNV | Missense_Mutation | novel | c.1625N>C | p.Leu542Pro | p.L542P | Q92542 | protein_coding | tolerated(0.14) | possibly_damaging(0.675) | TCGA-OL-A6VO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
NCSTN | insertion | Nonsense_Mutation | novel | c.724_725insGTCCCAAAGGATCAGGAGAGCCTACTGTCACCTAAGGCTCAC | p.Ile242delinsSerProLysGlySerGlyGluProThrValThrTerGlySerLeu | p.I242delinsSPKGSGEPTVT*GSL | Q92542 | protein_coding | | | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
NCSTN | SNV | Missense_Mutation | rs200800006 | c.892G>A | p.Ala298Thr | p.A298T | Q92542 | protein_coding | tolerated(0.54) | benign(0.121) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NCSTN | SNV | Missense_Mutation | | c.375N>C | p.Leu125Phe | p.L125F | Q92542 | protein_coding | tolerated(0.7) | benign(0) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
NCSTN | SNV | Missense_Mutation | | c.1144C>T | p.Pro382Ser | p.P382S | Q92542 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
NCSTN | SNV | Missense_Mutation | | c.412N>A | p.Val138Ile | p.V138I | Q92542 | protein_coding | tolerated(0.38) | benign(0.033) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
23385 | NCSTN | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | MK0752 | | |
23385 | NCSTN | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | RO 4929097 | | |
23385 | NCSTN | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | PF03084014 | | |
23385 | NCSTN | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | BMS-299897 | CHEMBL247471 | |
23385 | NCSTN | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | IC261 | IC261 | 20350806 |
23385 | NCSTN | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | GSI-136 | GSI-136 | |
23385 | NCSTN | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | CHEMBL463981 | BEGACESTAT | |
23385 | NCSTN | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | modulator | CHEMBL190083 | TARENFLURBIL | |
23385 | NCSTN | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | CHEMBL520733 | SEMAGACESTAT | |
23385 | NCSTN | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | MK0752 | | |